Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
Met primary endpoint of safety and tolerability in CCM patients with no…
GH Research to Provide Update on Phase 2b Trial with GH001 in TRD
DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS),…
Movement Network Foundation Launches Developer Phase of Public Mainnet
Announces Cornucopia: A Multi-Asset Liquidity Program for Public Mainnet Beta GRAND CAYMAN,…
ThoughtExchange Appoints former Clio, AlayaCare COO George Psiharis as CEO to Lead Next Phase of Growth
Former CEO, Dave MacLeod, led the search and will spearhead R&D and…
60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis
Investigational Review Board (IRB) approval has been granted for the open-label study…
STL strengthens leadership team to drive the next phase of growth
MUMBAI, India, Jan. 27, 2025 /PRNewswire/ -- STL (NSE: STLTECH), a leading…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal Cancer
Readout of ~1K patients at ASCO GI 2025 demonstrates that Signatera™ positive…
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025 16:05 ET | Source: Akero Therapeutics Inc. Investor webcast…
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer…